NCT02523976 2026-02-11
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
Clinical Trials
9 trialsNCT00287105 2023-05-24
ESPHALL
Rennes University Hospital
Phase 2 Completed
NCT01724879 2022-01-26
Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)
Goethe University
Phase 2 Completed
NCT00171223 2021-07-22
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
Novartis
Phase 2 Completed
NCT00171249 2021-07-22
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia
Novartis
Phase 2 Completed
NCT00171158 2021-06-25
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
Novartis
Phase 2 Completed
NCT00852566 2017-09-25
NordCML006
Norwegian University of Science and Technology
Phase 2 Completed
NCT00261846 2017-07-27
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
Pfizer
Phase 2 Completed
NCT00511303 2007-08-03
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia
University of Bologna
Phase 2 Completed